Shanghai Genomics is building the first novel drug discovery platform in China for cancer, inflammation and viral infection diseases; by utilizing in-house clinical biological, chemical and animal studies. This DNA-to-NDA platform will significantly speed up the process of gene to drugs at a fraction of the cost normally associated with drug development in developed countries.
Armed with the vast pool of knowledge generated from the Human Genome Project, we have focused on drug susceptible genes such as kinase, phosphatase, and protease. To better understand 300 carefully selected potential target genes, Shanghai Genomics has systematically analyzed their protein-protein interactions, gene expression profiles in disease tissues, protein function in disease-related signal transduction pathways and relevant animal models. These validated targets have created a solid foundation for our downstream drug development program.
Shanghai Genomics has discovered several new members of a tumor surface antigen family (RLs), which can be specifically recognized by immune killer cells (NK), and a group of new kinases involved in cell cycle regulation. These genes can be used as either diagnostic markers or high throughput screening targets. We are seeking pre-clinical stage compounds for license in China to take advantage of our efficient pre-clinical and clinical studies. Shanghai Genomics drug development programs are lead by our superior chemical synthesis abilities and sophisticated biotechnologies. To ensure the irreplaceable position of our products in domestic markets we have followed strict intellectual property protection procedures. Filing both domestic and PCT patents on proprietary drug leads and target discoveries also prepares Shanghai Genomics to enter into the global market.
|
